Cialis Side Effects: Which Ones Can Become Permanent?

What Side Effects Does Tadalafil Most Commonly Cause?

Tadalafil's most frequent adverse events are mild, transient, and tied directly to its mechanism of PDE5 inhibition. The FDA-approved prescribing information lists headache (15%), dyspepsia (10%), back pain (6%), myalgia (5%), nasal congestion (4%), and flushing (3%) as the most common reactions at the 20 mg dose. These resolve within 12 to 24 hours in most patients because tadalafil's half-life runs roughly 17.5 hours, longer than sildenafil's 3 to 5 hours but still finite. [1]

Why Back Pain and Myalgia Are Unique to Tadalafil

Back pain and muscle aches appear more frequently with tadalafil than with other PDE5 inhibitors. A pooled analysis of Phase III erectile dysfunction trials found back pain and myalgia rates of 6.5% and 5.7%, respectively, compared with under 2% for sildenafil [2]. The mechanism is thought to involve PDE11 inhibition in skeletal muscle, an off-target action tadalafil shares more than other agents in the class.

Symptoms typically peak at 12 to 24 hours post-dose and clear by 48 hours. Dose reduction from 20 mg to 10 mg cuts the incidence roughly in half.

Cardiovascular and Hemodynamic Effects

Tadalafil lowers mean systolic blood pressure by approximately 8 mmHg in normotensive men. That drop is clinically acceptable in isolation, but it becomes dangerous when tadalafil is combined with organic nitrates (nitroglycerin, isosorbide mononitrate) or alpha-blockers at supraphysiologic doses. The FDA label carries an absolute contraindication against concurrent nitrate use. [1]

In the TADALA-CAD study of men with stable coronary artery disease, tadalafil 20 mg did not increase adverse cardiac events over 12 weeks, reinforcing that the drug is cardiovascularly neutral in appropriately selected patients. [3]

Which Tadalafil Side Effects May Become Permanent?

Three adverse events associated with tadalafil carry documented potential for lasting or irreversible harm: NAION, sudden sensorineural hearing loss, and ischemic priapism. Each deserves separate analysis.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NAION is the most clinically serious potentially permanent side effect linked to tadalafil. It presents as sudden, painless, unilateral visual field loss, often noticed on waking. The FDA added a warning about NAION to all PDE5 inhibitor labels in 2005 after post-marketing case reports accumulated [4].

The proposed mechanism involves PDE5-mediated vasodilation reducing perfusion pressure to the optic nerve head, particularly in men with a "disc at risk" anatomy (small cup-to-disc ratio). A 2014 case-crossover study published in JAMA Ophthalmology (N=38) found an odds ratio of 2.15 for NAION within a 5-day exposure window after PDE5 inhibitor use. [5]

Visual recovery after NAION is partial at best. Roughly 40% of patients regain some vision over months, but complete recovery is rare, and the fellow eye remains at elevated risk. Any patient who develops sudden visual disturbance while taking tadalafil should stop the drug and seek emergency ophthalmologic evaluation within hours, not days.

Risk factors that increase NAION susceptibility include:

• Small optic disc cup-to-disc ratio (<0.2)
• Diabetes mellitus
• Hypertension
• Hyperlipidemia
• History of NAION in the contralateral eye

HealthRX Clinical Framework: Before prescribing tadalafil to a man over 55 with any two of the five risk factors above, ask the prescribing or reviewing physician to document a fundoscopic exam or ophthalmology clearance. This is not standard FDA-label language but reflects a harm-reduction tier used by the HealthRX medical team when the cumulative NAION risk profile is elevated.

Sudden Sensorineural Hearing Loss (SSNHL)

The FDA issued a safety communication in October 2007 requiring all PDE5 inhibitor labels to add a warning for SSNHL after a cluster of post-marketing reports [6]. SSNHL is defined as >30 dB loss across three contiguous frequencies occurring within 72 hours. It may be accompanied by tinnitus or vertigo.

The absolute incidence with tadalafil is not precisely quantifiable because SSNHL also occurs spontaneously (estimated at 5 to 27 cases per 100,000 person-years in the general population). The FAERS database contained 29 confirmed SSNHL cases involving tadalafil specifically as of the 2007 FDA review [6]. Most cases occurred within hours of dose ingestion.

SSNHL is a medical emergency. Prompt treatment with systemic corticosteroids within 72 hours (typically oral prednisone 60 mg/day tapered over 10 to 14 days, or intratympanic dexamethasone) offers the best chance of partial recovery. Without treatment, hearing loss from SSNHL is often permanent.

Tinnitus without objective hearing loss also appears in FAERS reports and, while less disabling, may persist for weeks to months after discontinuation.

Priapism and Subsequent Erectile Dysfunction

Priapism, defined as a penile erection persisting beyond four hours without sexual stimulation, appears in the tadalafil prescribing information as a rare adverse event. The mechanism involves excessive PDE5 inhibition causing sustained corpus cavernosum smooth-muscle relaxation and venous outflow obstruction. [1]

Ischemic priapism beyond four to six hours causes progressive hypoxia, acidosis, and cavernosal fibrosis. The endpoint, if untreated, is permanent erectile dysfunction from structural damage to erectile tissue. A 2011 review in the Journal of Sexual Medicine noted that ischemic priapism lasting more than 24 hours carries a risk of permanent erectile dysfunction exceeding 90%. [7]

Men using tadalafil at highest risk include those with:

• Sickle cell disease or trait
• Glucose-6-phosphate dehydrogenase deficiency
• Multiple myeloma or leukemia
• Concurrent use of other vasoactive drugs

Any erection lasting more than four hours requires immediate emergency department evaluation. Aspiration and intracavernosal phenylephrine are first-line interventions. Surgical shunting is reserved for refractory cases.

Tadalafil and Cardiovascular Events: Separating Signal from Noise

Some patients worry that Cialis can cause a heart attack. In well-selected populations, the data do not support that fear. A 2006 systematic review in the Annals of Internal Medicine (covering >8,000 men across 42 trials) found no statistically significant increase in myocardial infarction, stroke, or cardiovascular death compared with placebo. [8]

Sexual activity itself temporarily raises cardiac demand to roughly 3 to 5 METs, equivalent to climbing two flights of stairs. Men who cannot tolerate that level of exertion without symptoms should not use tadalafil regardless of the drug's direct cardiovascular profile. The Princeton III Consensus Panel recommended cardiovascular risk stratification before PDE5 inhibitor prescribing, stratifying patients into low-, intermediate-, and high-risk categories. [9]

Hypotension with Nitrates: An Absolute Contraindication

The interaction between tadalafil and organic nitrates is pharmacodynamic, not pharmacokinetic. Both agents increase cyclic GMP, and the combination can produce severe, life-threatening hypotension. The FDA label states this contraindication without qualification [1]. No dose adjustment rescues this combination.

Patients on nitrates who develop erectile dysfunction should discuss alternative strategies with their cardiologist. Tadalafil is not appropriate for this population.

Hypotension with Alpha-Blockers

The interaction with alpha-blockers (tamsulosin, doxazosin, terazosin) is more nuanced. The FDA label permits concurrent use of tadalafil 5 mg daily with alpha-blockers for benign prostatic hyperplasia (BPH), but cautions against higher as-needed doses, particularly with non-uroselective alpha-blockers. Orthostatic hypotension with syncope has been reported. [1]

Tamsulosin 0.4 mg is the alpha-blocker most studied alongside tadalafil, and the combination appears relatively safe at recommended doses based on Phase III BPH trial data.

Long-Term Safety: What Do Extended-Use Data Show?

Tadalafil 5 mg once daily for BPH and erectile dysfunction has long-term safety data extending to four years from the LVHF and LVAD-related PAH trials and from open-label extension studies in ED. A 2016 pooled safety analysis (N=1,173, treatment duration up to 26 weeks) found no new safety signals emerging beyond what was already in the label [10]. Back pain and myalgia showed slight attenuation with continued use, possibly reflecting patient selection.

Tadalafil and Melanoma Risk: A Contested Signal

A 2016 JAMA Internal Medicine cohort study raised concern that PDE5 inhibitor use was associated with increased melanoma risk (hazard ratio 1.21, 95% CI 1.02 to 1.43) [11]. Subsequent studies and a 2020 meta-analysis found the association attenuated substantially after adjusting for sun exposure and socioeconomic confounders, and no biologically plausible causal mechanism has been confirmed. This remains an open area of surveillance but does not currently change prescribing practice.

Vision Changes from Phosphodiesterase Cross-Inhibition

Tadalafil has lower PDE6 inhibition than sildenafil, which is why the classic blue-tint visual disturbance reported with sildenafil occurs much less frequently with tadalafil. PDE6 is concentrated in retinal photoreceptors. Transient color vision changes reported with tadalafil in clinical trials occurred in fewer than 1% of participants at 20 mg [1]. These effects resolve with drug clearance and are not associated with permanent retinal damage at approved doses.

Drug Interactions That Can Amplify Side Effects

CYP3A4 Inhibitors

Tadalafil is metabolized primarily by CYP3A4. Strong inhibitors including ketoconazole, itraconazole, ritonavir, and clarithromycin significantly raise tadalafil plasma concentrations. Ritonavir 200 mg twice daily raised tadalafil AUC by 124% in a formal pharmacokinetic study. The FDA label recommends a maximum dose of 10 mg every 72 hours for as-needed use when strong CYP3A4 inhibitors are co-administered. [1]

Higher systemic exposure increases the likelihood and severity of hypotension, back pain, and, theoretically, ocular perfusion pressure reduction.

CYP3A4 Inducers

Rifampin 600 mg daily reduced tadalafil AUC by 88%, rendering standard doses potentially ineffective. Dose increases in the presence of rifampin are not recommended because the unpredictability of enzyme induction makes dose titration unreliable.

Alcohol

Alcohol itself is a vasodilator. The combination of 0.7 g/kg alcohol with tadalafil 20 mg produced additional reductions in standing systolic blood pressure of approximately 7 mmHg in a dedicated PK/PD study. Patients should limit alcohol to two or fewer standard drinks when using tadalafil.

Tadalafil in Specific Populations: Adjusted Risk Profiles

Older Adults

Men aged 65 and older show tadalafil AUC approximately 25% higher than younger men due to reduced renal and hepatic clearance, not because CYP3A4 activity changes substantially with age. The FDA label does not require dose adjustment based on age alone, but the prescribing clinician should factor in polypharmacy, baseline blood pressure, and comorbid cardiovascular disease. [1]

Renal and Hepatic Impairment

Creatinine clearance below 30 mL/min prolongs tadalafil half-life meaningfully. The maximum recommended dose in severe renal impairment (CrCl <30 mL/min) is 5 mg, and once-daily dosing is not recommended. Child-Pugh Class C hepatic impairment contraindicates tadalafil use. [1]

Women

Tadalafil is FDA-approved for pulmonary arterial hypertension (as Adcirca, 40 mg once daily) in both men and women. Off-label use for female sexual dysfunction has been studied in small trials; safety data in women are not sufficient to draw firm conclusions about the permanence risks described above.

FDA Label Language and Post-Market Surveillance

The FDA's current tadalafil prescribing information (revised 2018) includes bolded warnings for:

1. Hypotension with nitrates or guanylate cyclase stimulators (absolute contraindication)
2. Cardiovascular risk stratification before use
3. NAION with instruction to discontinue immediately if sudden vision loss occurs
4. SSNHL with instruction to seek immediate care
5. Priapism with instruction to seek immediate medical care if erection lasts more than four hours [1]

The FDA Adverse Event Reporting System (FAERS) contains over 2,000 ocular adverse event reports across the PDE5 inhibitor class collected through 2020. Among tadalafil-specific reports, NAION, visual field defect, and blindness account for the largest share of serious ocular events. Reporting bias in FAERS means these numbers undercount actual incidence, but they confirm the signal is real and ongoing. [4]

The Endocrine Society 2018 clinical practice guideline on male hypogonadism notes that PDE5 inhibitors remain appropriate first-line pharmacotherapy for erectile dysfunction, including in men on testosterone replacement, provided contraindications are excluded [12]. The guideline does not enumerate additional long-term safety concerns beyond those in the FDA label.

What to Do If You Experience a Concerning Side Effect

Patients taking tadalafil should stop the drug and contact a physician or emergency services immediately if they experience:

• Sudden loss of vision in one or both eyes
• Sudden decrease or loss of hearing, with or without tinnitus
• Chest pain, dizziness, or fainting during or after sexual activity
• An erection that lasts more than four hours

For common side effects like headache, back pain, or dyspepsia, dose reduction from 20 mg to 10 mg or switching from as-needed to daily dosing at 5 mg often reduces symptom burden without requiring discontinuation. A prescribing clinician should guide any regimen change.